Leptin and interleukin-6 level in patients with hypertension and obesity combined with non-alcoholic steatohepatitis during treatment with sartans and statins

1. Amosova E.N.: From the treatment of atherosclerosis by modifying the forecast: Focus on lipidlowering therapy. Chapter 1. Sertse i sudyny, 33, 6, 2011Search in Google Scholar

2. Bablyak S.D. Khomyn A.M.: An experience of the use of combined antihypertensive therapy in aged women with long) lasting arterial hypertension. Medytsyna transportu Ukrainy, 2, 64, 2008.Search in Google Scholar

3. Boychak M.P.: Additional effects of angiotensin II receptor antagonists in the treatment of patients with hypertension. Therapia, 54, 37, 2011.Search in Google Scholar

4. Egorov I.E.: Hypertension: the evolution of approaches to treatment. Health of Ukraine, 2, 67, 2013.Search in Google Scholar

5. Gerasimova A.S., Oleinikov V.E., Yeliseyeva I.V.: The peculiarities of arterial hypertension course and involvement of the target organs in metabolic syndrome. International Medical Journal, 3, 22, 2008Search in Google Scholar

6. Gubergrits N.B. Lareva N.V.: Statins in hepatology: a «princess frog» or a «toad»? Contemporary gastroenterology [Suchasna gastroenterologia], 6, 78, 2011Search in Google Scholar

7. Ikejima H. et al.: Effects of telmisartan, a unique angiotensinreceptor blocker with selective prexisome proliferatoractivated receptor-gamma-modulating activity, on nitric oxide bioavaliability and atherosclerotic change. J. Hypertens, 26, 964, 2008.10.1097/HJH.0b013e3282f52c36Open DOISearch in Google Scholar

8. Khukhlina O.S., Gorbatiuk I.B.: The investigation of rosuvastatin and mosaprid influence on the changes of the blood lipid profile, the level of insulin resistance and bilelithogenicity in patients with chronic stone-free cholecystitis, in combination with obesity and ischemic heart disease. Clin. and expirem. Pathol., 10, 143, 2011.Search in Google Scholar

9. Kubik M. et al.: Telmisartan improves cardiometabolic profile in obese patients with arterial hypertension. Kidney Blood Press. Res., 35, 281, 2012.10.1159/000334951Search in Google Scholar

10. Mitchenko O.I. et al.: Leptin adiponectin index as a new additional surrogate marker of atherosclerotic lesions. Ukraiinskyj cardiologichnyj zhurnal, 2, 40, 2012.Search in Google Scholar

11. Nakayama S. et al.: Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertens Res., 31, 7, 2008.10.1291/hypres.31.7Search in Google Scholar

12. Neutel J.M.: Choosing among reninangiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy. Current Medical Research & Opinion, 26, 213, 2010.10.1185/03007990903444434Search in Google Scholar

13. Pérez-Castrillón J.L. et al.: Telmisartan effect’s on remodelling bone markers in hypertensive patients. Nutr Hosp., 27, 276, 2012.Search in Google Scholar

14. Solomenchyk T.M. et al.: Efficacy of Rosuvastatin in patients with hypertension of high cardiovascular risk. Liky Ukrainy, 9-10, 82, 2013.Search in Google Scholar

15. The ONTARGET investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med., 358, 1547, 2008.Search in Google Scholar

16. The TRANSCEND investigators. Effects of the angiotensinreceptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet, 372, 1174, 2008.10.1016/S0140-6736(08)61242-8Search in Google Scholar